Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
- MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
| MarketCap | 1.8B |
|---|---|
| PE Ratio | |
| PEG Ratio | -0.1 |
| P/B | 2.8 |
| P/S (ttm) | 2.9 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 28% |
| Held by Institutions % | 36% |
| 1 Day Vol Adjusted Return | -2.5 |
| 1 Month Vol Adjusted Return | 0.8 |
| 3 Month Vol Adjusted Return | 3.1 |
| 6 Month Vol Adjusted Return | -2.4 |
| 20 Days SMA Price ZScore | 0.4 |
| 50 Days SMA Price ZScore | 1.0 |
| 12 -26 Days PPO | 2.5 |
| 1 Month Average Short Volume Ratio | 49.1 |
| 1 Day Volume Change ZScore | 1.5 |
| 1 Month Daily Vol | 2.5 |
Stock news
In this segment of "Backstage Pass" on Motley Fool Live, recorded on July 27, Fool.com contributors Matt Frankel and Jason Hall discuss some of the reasons why it could be a good time to invest in the business. Matt Frankel: So Jason, why don't you give us a quick overview of Fulgent and why you doubled down on it or however much you added? This is a company that's very much grouped in with the COVID stocks, so Ming Hsieh, the founder of the company, has a long history of success as an entrepr...
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 6.85% and 2.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TEMPLE CITY, Calif., August 04, 2022--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent Genetics", "Fulgent", or the "Company"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2022.
TEMPLE CITY, Calif., August 04, 2022--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent Genetics", "Fulgent", or the "Company"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced it has launched a test for monkeypox that leverages the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test, which detects non-smallpox related orthopoxviruses, including monkeypox. Fulg
TEMPLE CITY, Calif., August 04, 2022--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent Genetics", "Fulgent" or the "company") today announced the addition of two therapeutic industry veterans to its board of directors. Dr. Michael Nohaile, Chief Scientific Officer of Generate Biomedicines ("Generate"), and Dr. Leonard Post, Chief Scientific Officer of Vivace Therapeutics ("Vivace"), who joined the company’s Board of Directors, effective August 1, 2022.
In the latest trading session, Fulgent Genetics, Inc. (FLGT) closed at $58, marking a -1.46% move from the previous day.